|By Business Wire||
|June 15, 2014 04:00 PM EDT||
Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a Preferred Provider agreement with Veristat.
Under this agreement, Veristat provides strategic statistical consulting and biometrics services, including study design, statistical analysis and data presentation, for a number of Karyopharm’s novel cancer programs, including acute myeloid leukemia, diffuse large B-cell lymphoma, Richter’s transformation, glioblastoma, gynecological malignancies, prostate cancer and squamous cell carcinomas.
Sharon Shacham, PhD, MBA, Karyopharm’s Founder, President and Chief Scientific Officer stated, “We sought a strategic partner and teammate for our programs who understands the therapeutic and regulatory aspects of our multiple trials with our novel nuclear export inhibitor Selinexor. We believe that we have found an important partner for Karyopharm given Veristat’s depth of experience in oncology and with novel therapeutics.”
John Balser PhD, President of Veristat noted: “We are very grateful and privileged to be chosen by Karyopharm to assist them in the development of their novel therapeutics. We are pleased to bring our experience, scientific expertise and enthusiasm to the many programs Karyopharm has underway. We are confident that our partnership with Karyopharm will help to accelerate their programs and to make a difference in patients’ lives.”
Veristat is exhibiting at the Drug Information Association (DIA) 2014 Annual Meeting in San Diego, California at booth #633 during the week of June 16, 2014.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The inhibition of XPO1 by Karyopharm’s lead drug candidate, Selinexor (KPT-330), a first-in-class, oral SINE compound, leads to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts. For more information, please visit www.karyopharm.com.
Veristat, Inc. is an innovative, science-focused clinical research organization (CRO) in its 20th year of providing expertise in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information about Veristat and the services provided please visit www.veristat.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm’s drug candidates. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations. Any forward-looking statements contained in this press release speak only as of the date hereof, and each of Karyopharm and Veristat expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.